Close Menu

single-molecule analysis

The sequencing firm said the COVID-19 pandemic had a negative impact on revenues, which totaled $17.1 million, down from $24.6 million in the prior-year period.

Asuragen will develop assays for PacBio's long-read next-generation sequencing systems, with an initial focus on developing a carrier screening assay.

Taiwan-based Personal Genomics, which is developing a new single-molecule sequencing platform, has previously sued PacBio for patent infringement in the US.

The sequencing firm reported total revenues of $15.6 million, with instrument revenue negatively impacted by shutdowns precipitated by COVID-19.

All three methods build on the use of methyltransferases to mark accessible regions of the genome, using nanopore sequencing to detect the modifications.

PacBio will try to take the Sequel II to the clinic in China with the help of Berry Genomics and is open to partnerships globally, including with Illumina.

Full-year 2019 revenues grew 16 percent and the firm booked $18 million in other income from Illumina, before their acquisition deal fell apart.

In a revised remedies proposal to the UK's Competition and Markets Authority, Illumina offered licenses to a wider swath of IP held by it and PacBio.

The firm reported $14.9 million in revenue, driven by an 80 percent increase in product revenues, beating Wall Street expectations.

In Nature this week: extension to uncultivated virus genome reporting standards, multiplex orthogonal CRISPR-based genome editing approach, and more.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.